A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis
Reason given: Sponsor Decision: The trial has been withdrawn with no plans to continue development.
Key facts
- Where
- Houston, Seattle, and Tampa, United StatesSee the 3 sites
- Phase
- Phase 2
Where in United States
- Clinical Trial NetworkHouston, United StatesNo longer taking part
- Swedish Medical Center-501 E Hampden AveSeattle, United StatesNo longer taking part
- University of South FloridaTampa, United StatesNo longer taking part
Trial details
- Who runs it
- Loxo Oncology, Inc.
- Trial code
- NCT06104683EU 2022-502376-24-00
- Record updated
- 27 March 2024
- Original description
The main purpose of this study is to assess efficacy and safety of pirtobrutinib in participants with relapsing multiple sclerosis.Read full original descriptionShow less
A Phase 2, Randomized Study of Pirtobrutinib Versus Placebo in Patients With Relapsing Multiple Sclerosis
The main purpose of this study is to assess efficacy and safety of pirtobrutinib in participants with relapsing multiple sclerosis.
Inclusion: Participants must have been diagnosed with relapsing MS; Participants must have one of the following; at least 1 documented relapse within the previous year, or; at least 2 documented relapse within the previous 2 years, or; at least 1 active Gd-enhancing brain lesion on an MRI scan in the past 6 months prior to screening.
Exclusion: Had a relapse of MS within 30 days prior to randomization; Have a history of another clinically significant neurological disease; Have had a diagnosis of primary progressive MS.